Are statin medications safe in patients with ALS?

References

• Krivickas LS, Yang J, Kim S, Frontera WR. Skeletal muscle fibre function and rate of disease progression in amyotrophic lateral sclerosis. Muscle Nerve. 2002; 26: 636–43
   PubMedGoogle Scholar
• Achari AN, Anderson MS. Myopathic changes in amyotrophic lateral sclerosis-pathologic analysis of muscle biopsy changes in 111 cases. Neurology. 1974; 24: 477–81
   PubMed Web of Science ®Google Scholar
• Süssmuth SD, Tumani H, Ecker D, Ludolph AC. Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum. Neurosci Lett. 2003; 353: 57–60
   PubMed Web of Science ®Google Scholar
• Ilzecka J, Stelmasiak Z. Creatine kinase activity in amyotrophic lateral sclerosis patients. Neurol Sci. 2003; 24: 286–87
   PubMed Web of Science ®Google Scholar
• Felice KJ, North WA. Creatine kinase values in amyotrophic lateral sclerosis. J Neurol Sci. 1998; 160(Suppl 1)S30–2
   PubMed Web of Science ®Google Scholar
• Schreiber DH, Anderson TR. Statin-induced rhabdomyolysis. J Emerg Med. 2006; 31: 177–80
   PubMed Web of Science ®Google Scholar
• Watson KE, Fonarow GC. The past, present, and future of statin therapy. Rev Cardiovasc Med. 2005; 6: 129–39
   PubMedGoogle Scholar
• Tousoulis D, Charakida M, Stefanadi E, Siasos G, Latsios G, Stefanadis C. Statins in heart failure. Beyond the lipid lowering effect. Int J Cardiol. 2007; 115: 144–50
   PubMedGoogle Scholar
• Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003; 289: 1681–90
   PubMed Web of Science ®Google Scholar
• Vladutiu GD, Simmons Z, Isackson PJ, Tarnopolsky M, Peltier WL, Barboi AC, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve. 2006; 34: 153–62
   PubMed Web of Science ®Google Scholar
• Phan T, McLeod JG, Pollard JD, Peiris O, Rohan A, Halpern JP. Peripheral neuropathy associated with simvastatin. J Neurol Neurosurg Psychiatry. 1995; 58: 625–8
   PubMed Web of Science ®Google Scholar
• Gaist D, García Rodríguez LA, Huerta C, Hallas J, Sindrup SH. Are users of lipid-lowering drugs at increased risk of peripheral neuropathy?. Eur J Clin Pharmacol. 2001; 56: 931–3
   PubMed Web of Science ®Google Scholar
• Folkers K, Langsjoen P, Willis R, Richardson P, Xia LJ, Ye CQ, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A. 1990; 87: 8931–4
   PubMed Web of Science ®Google Scholar
• Cutler RG, Pedersen WA, Camandola S, Rothstein JD, Mattson MP. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol. 2002; 52: 448–57
   PubMed Web of Science ®Google Scholar
• Bosel J, Gandor F, Harms C, Synowitz M, Harms U, Djoufack PC, et al. Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurons. J Neurochem. 2005; 92: 1386–98
   PubMed Web of Science ®Google Scholar
• Arnaud C, Braunersreuther V, Mach F. Toward immunomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc Med. 2005; 15: 202–6
   PubMed Web of Science ®Google Scholar
• Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 2007; 19: 5–20
   Google Scholar
• Gordon P, Miller R, Moore D. ALSFRS-R. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004; 5(Suppl 1)90–3
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999; 169: 13–21
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.
   Google Scholar
• Cohen J. Statistical Power Analysis for the Behavioral Sciences2nd edn. Lawrence Erlbaum Associates Inc, New Jersey 1988
   Google Scholar
• Miller R, Bradley W, Cudkowicz M, Hubble J, Meininger V, Mitsumoto H, et al. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology. 2007; 69: 776–84
   PubMed Web of Science ®Google Scholar
• Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomized trial. Lancet Neurol. 2007; 6: 1045–53
   PubMed Web of Science ®Google Scholar
• Desport JC, Torny F, Lacoste M, Preux PM, Couratier P. Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. Neurodegener Dis. 2005; 2: 202–7
   PubMed Web of Science ®Google Scholar
• Dupuis L, Oudart H, René F, Gonzalez de Aguilar JL, Loeffler JP. Evidencefor defective energy homeostasis in amyotrophic lateral sclerosis: benefitof a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci U S A. 2004; 101: 11159–64
   PubMed Web of Science ®Google Scholar
• Qureshi MM, Hayden D, Urbinelli L, Ferrante K, Newhall K, Myers D, et al. Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler Other Motor Neuron Disord. 2006; 7: 173–82
   PubMed Web of Science ®Google Scholar